Mercado Carmel L, Toy Brian C, Kistler Henry B, Moshfeghi Darius M
Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):497. doi: 10.3928/23258160-20160419-17.
A 92-year-old man presented with months of progressive blurry vision, worsening acutely in his right eye. He denied pain, diplopia, or photopsias. His history was significant for multiple myeloma, prostate cancer, and malignant melanoma of his right shoulder treated with local excision. He had local recurrence with hepatic metastasis of the melanoma treated with radiation and chemotherapy. On examination, his visual acuity was counting fingers in the right eye and 20/60 in the left eye. Amsler grid testing demonstrated metamorphopsia in the right eye. Fundus exam of the right and left eyes revealed multiple, elevated, pigmented choroidal lesions, with associated subretinal fluid in the right macula. This appearance is consistent with hematogenous metastasis of cutaneous malignant melanoma to the choroid and associated serous fluid-causing metamorphopsia. The patient was enrolled in a clinical trial combining plasmid IL-12 with pembrolizumab (Keytruda; Merck, Whitehouse Station, NJ). He passed away 2 months after initial presentation to our clinic. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:497.].
一名92岁男性因数月来视力逐渐模糊,右眼病情急剧恶化前来就诊。他否认疼痛、复视或闪光感。他有多发性骨髓瘤、前列腺癌病史,右肩部恶性黑色素瘤曾接受局部切除治疗。黑色素瘤出现局部复发并伴有肝转移,接受了放疗和化疗。检查时,他的右眼视力为眼前指数,左眼视力为20/60。阿姆斯勒方格表测试显示右眼有视物变形。双眼眼底检查发现双眼有多个隆起的色素性脉络膜病变,右眼黄斑区伴有视网膜下液。这种表现符合皮肤恶性黑色素瘤经血行转移至脉络膜并伴有浆液性液体导致视物变形。该患者参加了一项将质粒IL-12与派姆单抗(可瑞达;默克公司,新泽西州怀特豪斯站)联合使用的临床试验。他在首次到我们诊所就诊2个月后去世。[《眼科手术、激光与视网膜成像》。2016年;47:497。]